TrialLancet (London, England)2016

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Naomi B Haas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.